EUVIMEDEUVIMED entdecken
Crossref

L26/O-113 Good practice recommendations on ECS: who, when and how?

A. Capalbo

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Capalbo.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Expanded carrier screening (ECS) has emerged as a transformative approach in reproductive genetics, enabling the identification of individuals and couples who carry pathogenic variants in genes associated with autosomal recessive (AR) and X-linked (XL) conditions. With advances in high-throughput sequencing and decreasing costs, ECS has shifted from ancestry-based testing toward a pan-ethnic, population-based model. However, despite growing adoption—particularly within medically assisted reproduction (MAR)—its implementation remains highly heterogeneous across countries, clinics, and laboratories. The ESHRE working group developed these Good Practice Recommendations to provide a comprehensive framework for the responsible, ethical, and clinically meaningful implementation of ECS in MAR settings, including gamete donation. The document addresses clinical, technical, ethical, and organisational dimensions, aiming to promote harmonisation while respecting national contexts. The recommendations emphasise that ECS should primarily support reproductive autonomy by enabling informed decision-making. The preferred timing is the preconception period, particularly within MAR, where structured clinical pathways facilitate counselling and follow-up. Simultaneous testing of both partners is recommended to optimise efficiency, equity of information, and timely risk assessment, although sequential strategies may be acceptable in selected circumstances. Careful gene panel design is central to clinical utility. ECS panels should prioritise severe, early-onset, and clinically well-defined AR and XL conditions with strong gene–disease validity and reliable analytical performance. Transparent inclusion criteria, validated laboratory methodologies, and periodic panel re-evaluation are essential. Carrier frequency thresholds and foetal disease risk metrics should be applied thoughtfully to balance sensitivity, feasibility, and clinical relevance. Reporting should generally be limited to pathogenic and likely pathogenic variants, with clear policies regarding incidental findings. Genetic counselling is a cornerstone of ECS implementation. Pre-test counselling must address the scope, limitations, residual risk, potential outcomes, and reproductive implications of screening, ensuring voluntary and informed participation. Post-test counselling should be tailored to result categories—negative, low reproductive risk, or high reproductive risk—with mandatory specialised counselling for at-risk couples. In donation settings, matching strategies are recommended over donor exclusion based solely on carrier status, preserving equity while maintaining safety. When ECS identifies at-risk couples, reproductive options within MAR include preimplantation genetic testing for monogenic disorders (PGT-M), use of donor gametes, prenatal diagnosis, or proceeding without intervention. Evidence suggests high actionability for severe conditions, reinforcing the importance of thoughtful panel curation. Ethical considerations underpin the recommendations. While ECS promotes reproductive autonomy, proportionality, equity of access, avoidance of commercial pressure, and respect for the welfare of the future child must be safeguarded. Particular attention is given to vulnerable MAR populations and cross-border reproductive care. Finally, the document highlights the need for harmonisation of reporting standards, improved representation of diverse populations in genomic databases, expansion of counselling capacity, and ongoing evaluation of clinical utility and psychosocial impact. These ESHRE Good Practice Recommendations aim to support consistent, transparent, and ethically robust ECS implementation in MAR, ultimately strengthening reproductive care and informed choice across Europe and beyond.

Zitieren

APA

Capalbo, A. (2026). L26/O-113 Good practice recommendations on ECS: who, when and how?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.113

Vancouver

Capalbo A. L26/O-113 Good practice recommendations on ECS: who, when and how?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.113

BibTeX
@article{Capalbo2026,
  author = {Capalbo, A.},
  title = {L26/O-113 Good practice recommendations on ECS: who, when and how?},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.113}
}
Kostenlos starten →